Zai Lab Ltd (9688)

Currency in HKD
16.60
+0.13(+0.79%)
Closed·
Earnings results expected in 3 days
9688 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
16.5416.98
52 wk Range
12.3135.50
Key Statistics
Bid/Ask
16.59 / 16.60
Prev. Close
16.47
Open
16.6
Day's Range
16.54-16.98
52 wk Range
12.31-35.5
Volume
3.02M
Average Volume (3m)
10.88M
1-Year Change
-34.127%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
9688 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
23.76
Upside
+43.11%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Zai Lab Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

8 Buy
2 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 23.76
(+43.11% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Buy39.30+136.75%43.88Maintain08-09-2025

Earnings

Latest Release
26-02-2026
EPS / Forecast
-0.36 / -0.25
Revenue / Forecast
998.23M / 992.59M
EPS Revisions
Last 90 days

9688 Income Statement

Compare 9688 to Peers and Sector

Metrics to compare
9688
Peers
Sector
Relationship
P/E Ratio
−13.8x−3.2x−0.5x
PEG Ratio
−0.37−0.190.00
Price/Book
3.4x6.6x2.6x
Price / LTM Sales
5.3x14.8x3.3x
Upside (Analyst Target)
25.6%214.8%47.7%
Fair Value Upside
Unlock4.3%6.6%Unlock

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.

Employees
1784
Market
Hong Kong

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
37.22M33.13%613.07M
Other Institutional Investors
56.41M50.21%929.03M
Public Companies & Retail Investors
18.72M16.66%308.36M
Total
112.35M100.00%1.85B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC6.51%73,19,0481,20,545
RTW Investments, LP6.19%69,59,0321,14,615

FAQ

What Is the Zai Lab (9688) Share Price Today?

The Zai Lab share price today is 16.60.

What is the current Zai Lab (9688) share price and day range?

As of 04-05-2026, the Zai Lab share price is 16.60, with a previous close of 16.47. The share price has ranged from 16.54 to 16.98 today, while the 52-week range spans from 12.31 to 35.50.

What Is the Zai Lab Market Cap?

As of today, Zai Lab market cap is 18.96B.

What Is the Zai Lab (9688) Share Price Target?

The average 12-month share price target for Zai Lab is 23.76, with a high estimate of 43.10101801 and a low estimate of 15.01957713. 8 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +43.11% Upside potential.

What Is Zai Lab's Earnings Per Share (TTM)?

The Zai Lab EPS (TTM) is -1.60.

When Is the Next Zai Lab Earnings Date?

Zai Lab will release its next earnings report on 07-05-2026.

From a Technical Analysis Perspective, Is 9688 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Zai Lab Trade On?

Zai Lab is listed and trades on the Hong Kong Stock Exchange.

What Is the Stock Symbol for Zai Lab?

The stock symbol for Zai Lab is "9688."

How Many Times Has Zai Lab Stock Split?

Zai Lab has split 1 times.

How Many Employees Does Zai Lab Have?

Zai Lab has 1784 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.